Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1

Interventions

tetulomab tetraxetan lu-177 1sargramostim 1phenethyl isothiocyanate 1ibrutinib 1ethanolamine oleate 1cirmtuzumab 1Valganciclovir 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thiotepa 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Radiotherapy 1Polymerase Chain Reaction 1Pentetic Acid 1Ondansetron 1Methotrexate 1Lutetium-177 1Lutetium 1Ethanol 1Edetic Acid 1Biopsy 1Aprepitant 14-phenylbutyric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoproliferative Disorders × Valganciclovir × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡